IDT Australia Ltd
ASX:IDT
Intrinsic Value
IDT Australia Ltd. produces, develops and supplies pharmaceutical products. [ Read More ]
The intrinsic value of one IDT stock under the Base Case scenario is 0.131 AUD. Compared to the current market price of 0.095 AUD, IDT Australia Ltd is Undervalued by 27%.
Valuation Backtest
IDT Australia Ltd
Run backtest to discover the historical profit from buying and selling IDT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
IDT Australia Ltd
Current Assets | 10.4m |
Cash & Short-Term Investments | 4.6m |
Receivables | 4.5m |
Other Current Assets | 1.4m |
Non-Current Assets | 18.4m |
PP&E | 18.4m |
Current Liabilities | 3.2m |
Accounts Payable | 2.3m |
Accrued Liabilities | 612k |
Other Current Liabilities | 329k |
Non-Current Liabilities | 2.5m |
Long-Term Debt | 2.3m |
Other Non-Current Liabilities | 196k |
Earnings Waterfall
IDT Australia Ltd
Revenue
|
10.4m
AUD
|
Cost of Revenue
|
-2.4m
AUD
|
Gross Profit
|
7.9m
AUD
|
Operating Expenses
|
-15.7m
AUD
|
Operating Income
|
-7.7m
AUD
|
Other Expenses
|
1.2m
AUD
|
Net Income
|
-6.5m
AUD
|
Free Cash Flow Analysis
IDT Australia Ltd
What is Free Cash Flow?
IDT Profitability Score
Profitability Due Diligence
IDT Australia Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
IDT Australia Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
IDT Solvency Score
Solvency Due Diligence
IDT Australia Ltd's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Score
IDT Australia Ltd's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IDT Price Targets Summary
IDT Australia Ltd
According to Wall Street analysts, the average 1-year price target for IDT is 0.08 AUD .
Shareholder Return
IDT Price
IDT Australia Ltd
Average Annual Return | -2.28% |
Standard Deviation of Annual Returns | 50.25% |
Max Drawdown | -92% |
Market Capitalization | 33.4m AUD |
Shares Outstanding | 338 392 655 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
IDT Australia Ltd. produces, develops and supplies pharmaceutical products. The company is headquartered in Melbourne, Victoria. The firm is engaged in the supply of products and provision of research and development and other technical services within the pharmaceutical and allied industries. The firm specializes in the manufacture of Active Pharmaceutical Ingredients (API) and Finished Dose Forms (FDF), microbiological and analytical testing, clinical packaging and pharmacy services. The company provides services for new drug development and scale-up, commercial active drug manufacture as well as a various oral and injectable finished drug dose forms. Its sterile manufacturing suite is designed to liquid fill and lyophilise a range of sterile pharmaceutical and biopharmaceutical drug products. Its current goods manufacturing practices (cGMP) facilities manufactures a range of medicinal cannabis products for local and international markets.
Contact
IPO
Employees
Officers
The intrinsic value of one IDT stock under the Base Case scenario is 0.131 AUD.
Compared to the current market price of 0.095 AUD, IDT Australia Ltd is Undervalued by 27%.